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The pivotal role of epithelial cells is to secrete and absorb ions and water in order to allow the formation of a luminal fluid
compartment that is fundamental for the epithelial function as a barrier against environmental factors. Importantly, epithelial cells
also take part in the innate immune system. As a first line of defense they detect pathogens and react by secreting and responding to
chemokines and cytokines, thus aggravating immune responses or resolving inflammatory states. Loss of epithelial anion transport
is well documented in a variety of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, pancreatitis,
and cholestatic liver disease. Here we review the effect of aberrant anion secretion with focus on the release of inflammatory
mediators by epithelial cells and discuss putative mechanisms linking these transport defects to the augmented epithelial release
of chemokines and cytokines. These mechanisms may contribute to the excessive and persistent inflammation in many respiratory
and gastrointestinal diseases.
1. Introduction
The ion and water homeostasis, mediated by channels and
transporters at the apical and basolateralmembranes of secre-
tory epithelia that maintain a fluid compartment at the lumi-
nal surface, is essential for the function of different organ sys-
tems such as the airways, intestines, and pancreas [1, 2]. The
most abundant anions, chloride and bicarbonate, are secreted
through the apical cystic fibrosis transmembrane conduc-
tance regulator (CFTR) and calcium-activated chloride chan-
nel TMEM16A and anion exchangers of the SLC26A family.
At the basolateral plasma membrane (PM) chloride and
bicarbonate uptake are mediated by the sodium-potassium-
chloride cotransporter (NKCC1) and sodium-bicarbonate
cotransporters (NBC1), respectively [1] (Figure 1). Alterna-
tively, basolateral chloride entry into the cell is conducted by
the basolateral chloride-bicarbonate exchanger AE2 [3].
Secretory epithelial cells also play a pivotal role as part of
the innate immune system. Besides providing a physical bar-
rier by forming tight cell-cell contacts and a chemical barrier
by secreting antimicrobial peptides and mucins, epithelial
cells express a variety of pattern-recognition receptors that,
when triggered, activate the expression and release of a
number of chemokines and cytokines. These inflammatory
mediators in concert with the production of reactive oxygen
species (ROS) allow the epithelium to contribute to the
host defense and to recruit specialized immune cells [4–
7]. It is well established that the expression and function of
ion channels and transporters, including the anion channel
and transporters discussed in this review, are modulated
by chemokines and cytokines [8–12]. Examples for these
mechanisms include the inhibition and downregulation of
the epithelial sodium channel (ENaC) by IL-4 and IL-13
[10, 13, 14], the IL-4 and IL-13-mediated increase in function
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and expression of CFTR [13], and TMEM16A [15] as well as
pendrin (SLC26A4) [12, 16] and SLC26A9 [17]. The CFTR
expression and activity are increased by TNF𝛼 [18] and
decreased by IFN𝛾 [19, 20] and its function is attenuated
by CXCL8 via 𝛽2-adrenergic receptor (𝛽2-AR) dependent
mechanism [21] (Figure 1).
In contrast, little is known about the regulatory role
of anion transport on cytokine, in particular chemokine,
synthesis, and secretion of epithelial cell that serves as
amplifier and regulator of inflammation in conditions like
cystic fibrosis (CF), chronic obstructive pulmonary disease
(COPD), asthma, cholestasis, and acute pancreatitis. The
effects of aberrant anion transport activities in these diseases
and putative mechanisms linking them to the augmented
epithelial release of chemokines and cytokines are discussed
in this review.
2. Diseases Exhibiting Defective Epithelial
Anion Transport
2.1. Cystic Fibrosis. Cystic fibrosis (CF), the most common
lethal hereditary disease in the Caucasian population, is
caused by mutations in CFTR that lead to impaired anion
conductance at the apical membrane of secretory epithe-
lia [22–25]. More than 2,000 mutations in CFTR have
been described that confer a range of molecular, cellular,
and functional phenotypes [26, 27] and can be classified
according to these complex phenotypes as recently reviewed
[28]. Interestingly, mutants that are expressed at the apical
membrane in densities comparable to the wild-type (WT)
protein but are nonfunctional (e.g., G551D-CFTR) cause a
similar CF disease severity as mutants with strongly reduced
protein at the PM (e.g., ΔF508-CFTR) [27, 29], suggesting
that the loss of CFTR function rather than its physical absence
is required for the initiation of the disease.
CF is characterized by a multiorgan pathology mainly
affecting the upper and lower airway, gastrointestinal and
reproductive tract, and endocrine system [23, 25]. Pancreatic
disease in CF has a high penetrance and the pancreas is
the earliest intrauterine affected organ [30, 31]. Most CF
patients (80–90%) suffer from pancreatic insufficiency (PI), a
condition characterized by acinar atrophy, ductal irregularity,
fibrosis, deficiency of exocrine pancreatic enzymes, and
beta cell damage at late stages. Importantly, the level of
pancreatic damage in CF is linked to the genotype [32, 33].
Patients that retain sufficient exocrine pancreatic function
carry a small risk to develop pancreatitis [34, 35]. In the
lung, imbalanced epithelial ion secretion and mucus thick-
ening lead to decreased airway clearance and reoccurring
bronchopulmonary infections that cumulate in tissue dam-
age, the leading cause for morbidity and mortality in CF
[36–39].
It is widely accepted that CF lung disease is associated
with an excessive inflammatory response that is characterized
by massive neutrophil recruitment into the lumen driven by
augmented release of chemokines including CXCL8 by lung
epithelial tissue. Once recruited and activated the neutrophils
release antimicrobial peptides, neutrophil extracellular traps
(NETs), reactive oxygen species, and proteases [40–42]. The
sheer amount of neutrophil released serine proteases (neu-
trophil elastase (NE), proteinase 3, and cathepsin G) over-
whelms the antiprotease production resulting in protease-
antiprotease imbalance [43, 44]. Excessive amounts of NE
in the airway-surface liquid in turn induce CXCL8 expres-
sion [45, 46], upregulate mucin production [47, 48], cleave
antimicrobial peptides [49], and promote the degradation of
CFTR [50] further perpetuating the inflammatory response
that cumulates in progressive tissue damage. Despite their
excessive infiltration into the CF lung, CF neutrophils fail
to eradicate bacterial infections [41, 51]. A recent study
shows that CF neutrophils exhibit abnormal degranulation
responses and consequently impaired bacterial killing. Treat-
ment of G551D-CFTR patient with the potentiator ivacaftor
normalized the intracellular homeostasis and degranulation
of their neutrophils, thus improved bacterial killing [52].
These findings and studies reporting reduced phagolyso-
somal chlorination in CF neutrophils [53, 54] suggest an
intrinsic neutrophil function defect in CF. However, although
hyperinflammation in CF is acknowledged, it is under debate
whether the immunological aberrancy is directly caused
by loss-of-CFTR-function or is rather the consequence of
chronic bacterial infection (this controversy is reviewed in
[42, 55–57]).
2.1.1. Animal Models of CF. Animal models allow investi-
gating the early pathogenesis of CF and examining how
the lack of CFTR is linked to the host-defense defect of
the lung. Several CF mouse models exist, including null
[58, 59] and mutant form of CFTR [60–62] expressing
animals. However, none of these models develops sponta-
neous severe lung disease, characteristic of human CF. Yet
CF mice do secrete dramatically higher concentrations of
inflammatory mediators upon bacterial challenge, including
the chemokines keratinocyte chemoattractant (KC/CXCL1,
the functional CXCL8 analog in mice) and the macrophage
inflammatory protein 2 (mip-2/CCL3) that can be mea-
sured in the bronchoalveolar lavage (BAL) fluid [63, 64].
Concordantly, inhibition of CFTR in WT mice using the
inhibitor-172 exacerbates the acute inflammatory response in
an induced peritonitis model, including increased polymor-
phonuclear leukocyte infiltration and cytokine release [65].
The specificity of the inhibitor-172 however is questioned
by other studies [66–68]. Transgenic mice that overexpress
the 𝛽-subunit of the epithelial sodium channel (ENaC) in
the airway, mimicking the increased sodium reabsorption
found in human airway epithelia by many researchers [36,
37, 69], exhibit mucus obstruction, goblet cell metaplasia,
increased BAL levels of the chemokines CXCL1 and CXCL2,
neutrophilic inflammation, and poor bacterial clearance [70].
Since mice do not recapitulate all of the hallmarks of
human CF, considerable efforts were made to create other
animal models. CFTR−/− rats were recently created using
DNA editing and the resulting animals show a reduced
airway-surface liquid (ASL) height and submucosal gland
hypoplasia [71]. CFTR−/− and𝐶𝐹𝑇𝑅Δ𝐹508/Δ𝐹508 pigs as well as
CFTR−/− ferrets were generated by adeno-associated virus-
mediated gene targeting and somatic cell nuclear transfer
[72, 73]. CF pigs and ferrets develop spontaneous lung disease
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Figure 1: Schematic depiction of the anion transport pathways in secretory epithelia. Apical chloride (Cl−) and bicarbonate (HCO
3
−) efflux
is mediated by CFTR and TMEM16A and probably members of the SLC26A family. Basolateral chloride and bicarbonate entry is conducted
by cation cotransporters NKCC1 and NBC1, respectively. Alternatively chloride entry at the basolateral membrane is conducted by chloride-
bicarbonate exchange via AE2. Carbonic anhydrase (CA) catalyzes the de novo formation of bicarbonate. Examples for the cytokine-mediated
regulation of channel function or expression are indicated.
characterized by airway inflammation, airway remodeling,
impaired mucosal clearance, and bacterial infection [74–
76]. The clearance upon bacterial challenge in the lung of
both animal models is impaired likely as a result of the
decreased pH and therefore attenuated antibacterial proper-
ties of theASL [77, 78].The onset of pulmonary inflammation
however differs between CF pigs and ferrets. The CXCL8
and TNF𝛼 levels were increased in the CF ferret BAL at
birth, suggesting an inherent innate immunity defect [77].
In contrast neutrophil counts and CXCL8 levels were not
augmented in the neonatal CF pig BAL [74, 76]. Intriguingly,
the pancreas of newborn CF pig shows increased proportion
of innate immune cells and inflammatory response without
apparent infection [79]. Similarly, zebrafish that lacks func-
tional CFTR shows progressive destruction of the exocrine
pancreas accompanied by a significant increase in neutrophil
infiltration [80]. Thus, upregulation of chemokine secretion
that promotes neutrophil recruitment likely contributes to
the early onset of inflammation in these animals.
2.1.2. Human Studies. An early onset of excessive proinflam-
matory chemokine and cytokine release into the BAL of CF
infants has been reported, but whether this precedes bacterial
infection remains controversial [81–85]. CXCL8, neutrophils
counts, and the concentration of free elastase were promi-
nently increased in the BAL of CF patients in comparison to
healthy controls [82–84, 86]. Other inflammatory mediators
that are augmented in the CF lung include IL-6, IL-1𝛽, and
TNF-𝛼 [87], GM-CSF and G-CSF [88], IL-33 [89], HMGB1
[90], and the chemokine CCL18 [91]. Interestingly, a number
of studies reported a decrease of the anti-inflammatory
cytokine IL-10 in CF BAL [87, 92, 93]. By binding to the IL-
10 receptor, IL-10 inhibits signaling pathways including the
mitogen-activated kinase p38 and NF-𝜅B pathways that are
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associated with proinflammatory chemokine and cytokine
expression.
Using tracheal or bronchiolar grafts from CF and non-
CF human foetuses implanted into severe combined immun-
odeficient (SCID) mice Tirouvanziam and colleagues inves-
tigated the inflammatory state prior to any infection [94, 95].
Both upper and lower airway CF grafts showed increased
CXCL8 expression and leukocyte infiltration, but the inflam-
mation was more severe in the bronchiolar grafts leading to
progressive tissue destruction.These results provide evidence
that CF lung inflammation could arise solely from CFTR
mutations in sterile environment.
2.1.3. Cell Models. Increased CXCL8 expression in CF cell
lines and CF primary human bronchial epithelial cells has
been reported, both constitutively and following stimulation
with Pseudomonas aeruginosa or TNF-𝛼, implying CFTR-
dependent alteration in the innate immune response [96–
98]. However, elevated CXCL8 levels were not observed in
other cellular models [99–101], while in some studies CFTR
appeared to have a permissive role in CXCL8 secretion
[102, 103]. The interpretation of these results is difficult since
many derive from the comparison between clonally isolated
CF and non-CF cell lines. Isolation of individual clones
from heterologous cell populations, however, may favor
unrepresentative phenotypes as clonal variations can exceed
the underlying differences in the regulated CXCL8 secre-
tion [67]. The genetic heterogeneity and possible epigenetic
modification due to the repeated infection and inflammation
in CF [104] restrict the comparability of primary human
cells from CF patients and healthy individuals. However, a
number of studies elegantly circumvented these limitations.
Inhibition of CFTR function by continuous treatment with
the inhibitor-172 in differentiated primary airway epithelial
cells resulted in increased constitutive CXCL8 secretion that
was further augmented by Pseudomonas aeruginosa infection
[105]. CFTR inhibition by gene knockdown in the human
intestinal epithelial cell lines Caco-2/15 and HT-29 [106]
as well as in human the human airway epithelial cell line
Calu-3 [107] similarly increased CXCL8 secretion. In another
approach human CF respiratory epithelial models with the
inducible expression of either CFTR or TMEM16A were
generated. Induced expression of WT-CFTR or TMEM16A
attenuated the proinflammatory chemokine CXCL8, CXCL1,
and CXCL2 and cytokine IL-6 expression under air-liquid,
but not liquid-liquid interface culture [67]. Likewise, tran-
sient lentiviral transduction that conferred the expression of
WT-CFTR reduced CXCL8 secretion of primary human CF
bronchial epithelia [67]. Interestingly, the expression of the
nonfunctional G551D-CFTR or WT-CFTR in combination
with channel inhibition failed to attenuate CXCL8 release,
suggesting that CFTR-mediated anion transport activity at
the apical PM is required to reduce the proinflammatory
chemokine and cytokine secretion [67].
2.2. Chronic Obstructive Pulmonary Disease. Chronic ob-
structive pulmonary disease (COPD), encompassing two
clinical phenotypes, chronic bronchitis, and emphysema, is
attributed to the exposure to cigarette smoke and other
environmental toxins [108, 109]. Genetic factors such as 𝛼1-
antitrypsin gene mutations are also associated with disease
[110]. COPD affects 64million people and currently is the 4th
leading cause of mortality worldwide [111]. COPD is charac-
terized by persistent airflow limitation, chronic inflammatory
responses, excessivemucus production, and recurrent cough,
concordant to the CF lung phenotype. COPD shares sev-
eral other clinical, immunological, and biochemical features
with CF. Both are characterized by reduced mucociliary
clearance, goblet cell metaplasia, chronic bacterial infections,
excessive innate immune responses, and persistent neu-
trophilic inflammation. In comparison with CF, however, the
inflammatory response in COPD includes more pronounced
involvement of the adaptive immune system. An inverse
correlation between the number of CD8+ T cells and the
CD4+/CD8+ ratio to the lung function has been observed
[112–114]. The CD8+ T cells release perforins and cause
cytolysis and apoptosis of alveolar epithelial cells that is
correlated to emphysema [115, 116].
The phenotypic similarity between CF and COPD raises
the possibility that CFTR inactivation and/or downregulation
may play an important role in the pathogenesis of COPD.
Indeed, a number of studies support this hypothesis. (i)
COPD disease severity is inversely correlated with CFTR
protein expression [117]. (ii) CFTR function and expres-
sion are markedly attenuated in the respiratory epithelia
of smokers and patients suffering from COPD [118, 119].
(iii) CFTR downregulation was observed upon cigarette
smoke or cigarette smoke extract exposure of respiratory and
intestinal epithelial cultures [120–122]. (iv) Cigarette smoke
decreases the level of CFTR in lipid rafts in mice leading to
defective autophagy [123]. Overall, these studies suggest that
an acquired loss of CFTR function might contribute to the
pathogenesis of COPD.
The inflammation characteristics of COPD also resemble
that seen inCF. Cigarette smoke extract and acrolein, a smoke
component, have been shown to increase the CXCL8 mRNA
stability by activating the p38MAPK/MK2 signaling pathway
[124]. Gene expression levels of CXCL8, IL-6, CCL2, and
CCL8 were elevated in both smokers and COPD patients
[125]. This is consistent with the increased levels of CXCL1,
CXCL8, and CCL2 in induced sputum and/or BAL fluid [109]
and the augmented levels of CCL18 in the serum of COPD
patients [126].
2.3. Asthma. Asthma affects approximately 300 million peo-
ple worldwide. Between 5 and 15% are classified as severe
asthmatics, specified by a state of heightened morbidity that
is refractory to normal pharmacological treatment. Asthma is
characterized by airway hyperresponsiveness (AHR), tissue
remodeling as indicated by an increased proportion of airway
smooth muscle in the airway wall [127], and chronic airway
inflammation that together results in reversible airflow
obstruction [128]. In severe asthmatics’ sputa, besides hall-
marks of allergic inflammation, there is increased neutrophil
presence that is correlated with lowest lung function and
worst asthma control [129]. The increase in smooth muscle
mass leads tomore airway constriction and contributes to the
inflammatory milieu, including synthesis of the neutrophil
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chemoattractant CXCL8 in severe asthmatics [130]. Recent
studies in the CFTR knockout pig [131] and using TMEM16A
inhibitors in mouse and human airway smooth muscle [132,
133] support a role of these anion channels in smooth muscle
hyperresponsiveness. Moreover, as described in the previous
sections, links between defects in anion transport in epithelial
cells and increased CXCL8 production may have interesting
parallels in asthmatic airway smooth muscle to regulate
the inflammatory milieu, particularly in severe asthmatics.
The intricate connection between inflammation and anion
transport in airway smooth muscle is reviewed elsewhere
[134].
Current understanding suggests that beyond the smooth
muscle phenotype, the airway epithelium is a key player in the
pathology of asthma [135]. In addition to goblet cell hyper-
or metaplasia and mucus hypersecretion [136–138], the asth-
matic airway epitheliumexhibits barrier defects [139, 140] and
increased release of the chemokines and cytokines CXCL8,
IL-6, GM-CSF, TGF-𝛽1, IL-13, and IL-1𝛽 [141, 142] that are
capable of triggering both allergic (Th2-mediated [143]) and
neutrophilic (Th17-mediated [144]) inflammation. Moreover,
the ratio of CXCL8 to the anti-inflammatory lipid mediator
lipoxin A4 is increased in severe asthmatics, favoring proin-
flammatory environment that promotes neutrophil recruit-
ment [145]. Eicosanoids synthesis occurs via the cellular
cooperation between structural cells (such as epithelial cells)
and immune cells (like neutrophils). Changes in substrate
availability (arachidonic acid (AA) versus docosahexaenoic
acid (DHA)) can skew the inflammatory response, with
allergic individual showing lower levels of DHA [146]. In a
murine model of asthma, the proinflammatory balance was
reversed using the vitamin A-derivative fenretinide to favor
DHA over AA [147].
Some of these epithelial defects are reminiscent of the
changes observed in cystic fibrosis. For example, in CF imbal-
ance increasing the AA/DHA ratio has also been observed
[148] that can be ameliorated with fenretinide in a CF mouse
model [149]. Indeed at least 50% of CF patients show signs of
airway hyperresponsiveness and bronchodilator treatment-
reversible airway obstruction [150–153], a condition referred
to as “CF asthma” [154, 155]. Concordantly, studies found
an increased percentage of asthma patients to be carriers
of mutations in CFTR [156–158] and the nasal potential
difference values of some of these patients scored in the CF
range [157]. In addition to CFTR, the involvement of anion
transport in the pathophysiology of asthma is suggested by
aberrant expression of other epithelial anion transporters. (i)
The expression of the anion exchanger pendrin (SLC26A4)
that functions to import chloride from the ASL in exchange
to bicarbonate and thiocyanate [159] is upregulated in the
asthmatic airway epithelium likely as a consequence of Th2
cytokine (IL-4 and IL-13) signaling [160, 161]. Interestingly,
pendrin overexpression alone is sufficient to trigger mucus
hypersecretion, hyperresponsiveness, and elevated secretion
of the chemokines CXCL1 and CXLC2 that in turn lead to
neutrophil infiltration into the airway [162]. (ii) A polymor-
phism in the 3󸀠 UTR of SLC26A9 that functions as CFTR-
regulated chloride-bicarbonate exchanger or chloride chan-
nel [163–165] is associated with reduced protein expression
and an increased risk for asthma [17]. (iii) The calcium-
activated chloride channel TMEM16A expression in airway
secretory cells is increased in asthma and correlates with
mucus hypersecretion [132].
Taken together these evidences show an important role of
the airway epithelium to regulate the inflammatory balance
in asthma in addition to mucus hypersecretion. Thus, anion
transport can significantly influence neutrophil recruitment
via increased chemokine synthesis, which is particularly
important for the more severe form of the disease.
2.4. Pancreatitis. Acute pancreatitis (AP) is a sudden inflam-
matory disorder of the pancreas. AP is one of the most com-
mon disorders requiring acute hospitalization among the GI
diseases [166]. In its chronic form, pancreatitis (CP) can lead
to decreased quality of life with continuous pain, diarrhoea,
maldigestion, and consequently weight loss. Moreover in
some cases, on the base of chronic inflammation, pancreatic
ductal adenocarcinoma can develop. The human exocrine
pancreas consists of twomain secretory cell types: ductal and
acinar cells. The two cell types, as a functional unit, interact
closely to mediate the secretion of the pancreatic juice and
have a conjoint role in the pathogenesis of pancreatitis [167].
Acinar cells synthetize, store, and secrete digestive zymogens
that under physiological conditions are carried along the
ductal system into the duodenum. AP originates from the
premature activation of pancreatic zymogens, leading to the
autodigestion of the pancreas that causes the recruitment
of inflammatory cells. In addition, acinar cells produce
a large amount of protons which are secreted with the
pancreatic zymogens resulting in acidic fluid [168]. Ductal
cells secrete a bicarbonate-rich, alkaline fluid that is required
to neutralize the acinar acid load and carry the zymogens
into the duodenum and that acts as a protective mechanism
to prevent premature zymogen activation [169]. The ductal
secretion contains up to 140mM HCO
3
− that is achieved
by the concerted activity of anion transporters. Basolateral
Na+-HCO
3
− cotransporters, Na+/H+ exchangers, and H+-
ATPases mediate HCO
3
− uptake into the epithelial cells.
On the luminal side CFTR in concert with SCL26A family
Cl−/HCO
3
− exchangers, specifically SLC26A6 (PAT1) and
SLC26A3 (DRA), mediate the bicarbonate secretion. DRA
serves as 2Cl−/1HCO
3
− exchanger, whereas PAT1 functions
with 1 : 2 Cl− : HCO
3
− stoichiometry that enables reaching
the high bicarbonate concentration characteristic for the
pancreatic juice [170, 171]. A direct molecular interaction
between CFTR and SLC26A6 and A3 has been observed
that results in reciprocal activation of both CFTR and the
Cl−/HCO
3
− exchangers [172, 173]. However, until now the
exact role of SLC26A6 and SLC26A3 in the pancreatic ductal
bicarbonate secretion remains controversial [174].
Etiological factors for AP mainly include biliary disease
and alcohol consumption. Interestingly, these factors have
been shown to impair the ductal bicarbonate transport.
(i) Ethanol and its nonoxidative metabolites decrease the
CFTR activity, mRNA expression, and its stability at the
PM [175, 176]. (ii) At high concentration nonconjugated
bile acids impair the ductal bicarbonate and fluid secre-
tion by inhibiting ion transporters (Na+/H+ exchangers,
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Na+-HCO
3
− cotransporters, and Cl−/HCO
3
− exchangers)
and by causing intracellular calcium overload that leads to
mitochondrial damage and ATP depletion and could also
affect CFTR [177–180]. (iii) Recent studies suggest that smok-
ing increases the risk for pancreatitis [181–183]. Acrolein, a
component of cigarette smoke, has a systematic inhibitory
effect on CFTR activity [184] and therefore likely contributes
to the CFTR inhibition in pancreatic ducts. (iv) Intra-
acinar [185] or intraductal [186, 187] premature activation
of trypsinogen to trypsin is a key event in the initiation of
pancreatitis. Trypsin inhibits CFTR-mediated ion transport
by a PAR-2 dependent pathway, thus leading to a decreased
luminal pH that further accelerates the trypsinogen autoac-
tivation [169]. (v) Lastly, heterozygous carriers of CFTR
mutations have increased risk to develop pancreatitis [188–
197]. The consequences of CFTR mutations on pancreatic
function include high protein content and low-flow secretion
that frequently results in obstruction and the destruction of
the gland.Most CF patients with pancreatic insufficiency (PI)
carry “severe” mutations on both alleles that result in the loss
of exocrine function. In case “severe” CFTRmutation on one
allele is paired with “mild” CFTR mutation on the second
allele, most patients retain sufficient exocrine function for
digestion, referred to as pancreas sufficient phenotype (PS)
[198–200]. Because the exocrine function is necessary for the
initiation of pancreatitis, the risk for pancreatitis is higher
for those mutations manifesting in PS CF phenotype [201].
Interestingly, the CFTR variant R75Q, which has selective
bicarbonate transport defect, is associated with pancreatitis
but not classical CF. Overall, the aforementioned studies indi-
cate that the alteration of pancreatic ductal anion transport
plays a role in the development of pancreatitis, suggesting
that CFTR could be a possible therapeutic target for AP
[32].
AP results in local and systematic overproduction of
inflammatory mediators [202]. Characteristic hallmark of
the disease is the increased serum levels of CXCL8 and
IL-6 as well as often IL-1 and TNF-𝛼. CXLC8 and IL-
6 serum levels correlate with disease severity [203, 204].
Similar to the CF airway epithelia, it is likely that the
pancreatic epithelium itself is at least partly accountable
for the augmented chemokine and cytokine production and
therefore plays a role in the exacerbation of the pancreatic
inflammation. This is supported by the expression of IL-
33, IL-6, and CXCL8 in stressed acinar cells [205–208] as
well as CXCL8 expression in pancreatic duct cells [209].
Furthermore, pancreatic ductal adenocarcinoma cell lines
(CAPAN-1 and CAPAN-2) exhibit basal and LPS induced
secretion of CXCL8 and IL-6 [210]. The results of these
studies raise the intriguing possibility that impaired anion
transport in the pancreatic ductal system could increase
chemokine and cytokine secretion and therefore contribute
to the progression of pancreatitis.
2.5. Cholestatic Liver Disease. Cholangiopathies, chronic
progressive liver diseases (e.g., primary sclerosing cholan-
gitis or primary biliary cirrhosis) characterized by chronic
cholestasis, are frequently caused by drugs and antibiotics
and are common in CF increasing the risk for mortality
[211]. Cholestasis is bile flow stagnation that could result
from either the failure of the bile formation in the liver
cells (intrahepatic) or the blockade of the ductal secretory
mechanism (extrahepatic), responsible for washing biliary
secretion away from the hepatocytes. CFTR is expressed at
the apical membranes of cholangiocytes and the gallbladder
epithelium [212], where it acts as chloride channel. CFTR
promotes chloride efflux to generate a luminal chloride
gradient, the driving force for bicarbonate secretion via
AE2 mediated chloride/bicarbonate exchange resulting in
bicarbonate-rich choleresis [213, 214]. CFTR also regulates
cholangiocyte secretion by stimulating ATP release into the
ductal lumen. Luminal ATP triggers apical P2Y receptors
resulting in calcium mobilization, which in turn activates
TMEM16A-mediated bicarbonate secretion [215]. Accord-
ingly, dysfunction of CFTR results in low ductal pH, thick-
ened bile, impaired bile flow, and biliary obstruction [216,
217]. This condition leads to accumulation of hydrophobic
bile acids and results in periductal inflammation [218, 219].
Similar to the lung epithelium, human biliary epithelial
cells participate in the innate immunity.They express various
Toll-like receptors and secrete chemokines and cytokines as
well as antimicrobial factors [220].Therefore these cells play a
crucial role in the pathogenesis of different cholangiopathies,
such as primary biliary cholangitis and biliary atresia [221–
223]. Cultured biliary ductal epithelial cells secrete CXCL8
and CCL2 [224, 225] that drive neutrophil infiltration [226].
In addition several other chemokines, including CXCL1,
CXCL5, CXCL6, CCL3, CCL4, CCL5, and CXCL10, are
expressed by human biliary epithelial cells under both basal
and stimulated conditions [227].
One study showed that a combination of proinflam-
matory cytokines inhibits bile ductular secretion through
attenuating AE2 and CFTR function that is impeded by the
inhibition of cAMP formation in isolated single biliary ductal
units [228]. Other studies however highlighted the role of
CFTR function in the innate immune response of the biliary
epithelium. Dextran sodium sulphate induced colitis results
in an induced inflammatory cholangiopathy in CF but not
WT mice [229, 230]. Indeed, downregulation of CFTR in
progressive familiar intrahepatic cholestasis and reducedAE2
in primary biliary cirrhosis patients have been reported [231,
232]. Additionally, non-CF-causing CFTR mutations have
been associated with primary sclerosing cholangitis in some
patients [233, 234], further supporting the role of CFTR in
these diseases.
3. Putative Mechanisms Linking Aberrant
Anion Transport to the Dysregulated
Epithelial Chemokine Release
The inherited (CF) or acquired (COPD, asthma, pancreatitis,
and cholestasis) loss of epithelial anion transport is corre-
lated to the increased inflammation driven by the release
of chemokines and subsequent immune cell infiltration of
the respective organs (Table 1). While in some of the dis-
cussed diseases the causality of these events is incompletely
established, there is little doubt that loss of epithelial CFTR
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Table 1: Anion transport activity changes and proinflammatory chemokine and cytokine secretion in different diseases.
Disease Transporter/channel function Augmentedchemokines/cytokines
Airway system
CF CFTR ↓
CXCL8, CXCL1, CXCL2, CCL3,
CCL18, IL-1𝛽, IL-6, IL-33, TNF𝛼,
GM-CSF, G-CSF, HMGB1
COPD CFTR ↓ CXCL8, CXCL1, CCL2, CCL8,CCL18, IL-6
Asthma
CFTR∗
SLC26A4 ↑
TMEM16A ↑
SLC26A9 ↓
CXCL8, IL-1𝛽, IL-6, IL-13,
TGF-𝛽1, GM-CSF
Gastrointestinal system
Pancreatitis
CFTR∗
CFTR ↓
SLC26A3/A6 ↓
CXCL8, IL-1, IL-6, TNF-𝛼
Cholestatic liver diseases
CFTR∗
CFTR ↓
AE2 ↓
CXCL8, CXCL1, CXCL5, CXCL6,
CXCL10, CCL2, CCL3, CCL4,
CCL5,
CFTR∗: carriers of CFTR mutations have an increased risk to develop disease.
Table 2: Clinical trials for CF therapy indirectly targeting the lack of CFTR-mediated anion transport in the lung by ion-replacement or
activation of alternative anion channels.
Therapeutic approach Compound Type ofadministration Result References
Mucus rehydration Hypertonicsaline Nebulized
Modest increase
in lung function [241, 242]
Antioxidant
treatment
GSH Nebulized
Small or no
effect on lung
function
[288, 289, 312]
N-acetylcysteine Oral Modest increasein lung function [291, 294]
TMEM16A function Denufosol Inhaled
Small or no
effect on lung
function
[305, 313]
function is the primary cause for CF. This raises the question
how the lack of anion transport leads to the described disease
pathogeneses ormore specifically which chemical or physical
alterations, caused by the lack of chloride, bicarbonate, or
other anion transport, trigger the disease mechanisms.
3.1. Chloride Transport. The loss of CFTR-mediated chloride
transport resulting in a decreased ASL height was pro-
posed as primary causes of impaired mucociliary clearance,
recurrent bacterial infection, and chronic neutrophilic lung
infiltration in CF [36, 235, 236]. Reduced ASL height was
observed in primary human CF airway epithelial cultures
[236], human CF airway biopsies [237], CF ferret tracheas
[77], and CF rat tracheas [71]. However, it is under debate
whether CFTR inhibits the ENaC channel to prevent sodium
hyperabsorption, which if this inhibition is lost contributes
to the decreased ASL height [235, 238–240]. To counter-
act the reduced ASL height by rehydrating the mucus in
CF, administration of nebulized hypertonic saline (HTS)
was proposed. Administration of 7% HTS increased the
mucociliary clearance and lung function and decreased
the frequency of exacerbations [241, 242] (Table 2). In cell
models hyperosmolarity increases the CXCL8 production by
activating the p38 mitogen-activated protein kinase pathway
[243, 244]. In contrast, in the sputum of CF patients HTS
had either no effect [245, 246] or decreased CXCL8 levels
and reduced the neutrophil chemotactic efficiency [247].
The latter observation is consistent with the HTS-mediated
release of glycosaminoglycan boundCXCL8 that promotes its
proteolytic cleavage and reduces the half-life and function of
CXCL8 as neutrophil chemoattractant [247–249]. This leads
to a reduced number of neutrophils in the CF sputum after
HTS treatment [246]. A direct role of reduced ASL height in
the augmented neutrophil chemotaxis in CF was suggested
by a study of WT and ΔF508-CFTR tracheal epithelial cells
[250]. Here, Pseudomonas aeruginosa infection increased
the overall apical and basolateral release of the chemokines
CXCL1, CXCL2, CXCL5, and CXCL10 to a similar extent
in CF and WT epithelial cells. However, when the apical
chemokine concentration was adjusted to the reduced ASL
volume in CF, a significantly increased concentration gra-
dient across the epithelial monolayer became apparent that
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explains the doubled transmigration of neutrophils across the
CF monolayers [250] (Figure 2(a)).
3.2. Bicarbonate Transport. Lack of bicarbonate transport at
the apical membrane of epithelia results in reduced pH of
the epithelial lining fluid as indicated by measurements of
the ASL, bile, or pancreatic fluid in CF [77, 78, 216, 251–254].
This pH difference might be attributed to the lack of CFTR-
mediated bicarbonate transport [255, 256] or to the absence
of CFTR-mediated regulation of the chloride/bicarbonate
exchanger pendrin or other members of the SLC26 family
[159, 163, 257]. The pH difference is augmented by the
nongastric H+/K+ adenosine triphosphatase ATP12A activity
that in human and pig mediates H+ transport into the ASL
[258].
Reduced ASL bicarbonate and pH could provoke CF
and CF-like phenotypes by multiple mechanisms. (i) Mucins
packaging in goblet cell granules requires the presence of high
intragranular calcium concentrations and acidic pH. Upon
exocytosis, calcium chelation by bicarbonate and normal
ASL pH facilitate mucin unfolding, prerequisite for their
proteolytic cleavage and release from the cells surface [259,
260]. Impaired mucus detachment in CF pig submucosal
glands and attenuated mucus release in CF mouse intestine
highlight the importance of this mechanism [261–263]. In
addition, the increased viscosity of mucins at acidic pH
could contribute to the mucociliary clearance defect in CF
[264]. (ii) Reduced ASL pH attenuates the bactericidal effect
of antimicrobial peptides, key components of the innate
immune response of the lung. pH-dependent activity was
shown for lysozyme, lactoferrin, 𝛽-defensin-3, and LL-37 and
a deleterious effect on their synergistic bactericidal properties
upon pH-reduction was observed [78, 265]. (iii) The reduced
ASL pH may also directly activate chemokine and cytokine
expression and release by activating one or more of the
following acid-sensing signaling pathways (Figure 2(b)).
(a) Proton-sensing G-protein-coupled receptors, including
GPR4, GPR65 (TDAG8), GPR68 (OGR1), and GPR132
(G2A), regulate the inflammatory response among other
functions [266]. Upon activation by acidic pH GPR4 pre-
dominantly signals via the GS pathway resulting in activation
of cAMP formation [267, 268] and increased expression of
inflammatory genes including chemokines (CXCL2, CXCL8,
and CCL20), cytokines, adhesion molecules, NF-𝜅B pathway
genes, and stress response genes [269]. GPR68, which is
inactive at pH 7.8 and fully activated at pH 6.8, mainly acts
through Gq [268]. It is expressed in airway epithelia and
stimulates the phospholipase C activity as well as intracellular
Ca2+ signaling and has been implicated in the acid-induced
mucin5AC and IL-6 secretion [270, 271]. (b) The activity of
the receptor tyrosine kinases ErbB1 and ErbB2 is increased
by low extracellular pH [272], which can contribute to the
increase in CXCL8 production [273]. (c) The short palate
lung and nasal epithelial clone 1 (SPLUNC1) is a pH-sensitive
regulator of ENaC and is unable to inhibit ENaC in the acidic
CF airway environment [252]. Thus, the ensuing increased
ENaC activity may result in decreased ALS volume [274]
that can trigger augmented chemokine signaling as discussed
above.
Aberrant mucin release and reduced bactericidal prop-
erties of the lining fluid could promote chronic bacterial
infection that in concert with augmented chemokine and
cytokine secretionwould lead to the hyperinflammatory state
seen in CF and other diseases. However, CFTR mutants like
R75Q which have normal chloride but selective disruption of
bicarbonate conductance do not cause classical CF [195] but
are associated with recurrent acute and chronic pancreatitis
[198].
3.3. Glutathione and Thiocyanate Transport. Another poten-
tial mechanism to perpetuate the imbalance in chemokine
production in CF and perhaps other inflammatory disorders
is oxidative stress arising from oxidant-antioxidant imbal-
ance. Besides transporting chloride and bicarbonate, CFTR
may serve as an efflux channel for reduced glutathione (GSH)
[275, 276] and thiocyanate [277, 278].The ASL concentration
of GSH was estimated in the 275–430𝜇M range in healthy
individuals [279, 280]. In contrast in CF patients total GSH
concentrations are reduced to 92 𝜇Mbut the concentration of
the oxidised form (GSSG) was not affected by the absence of
CFTR activity, thus shifting the redox potential from−175mV
to −128mV [280]. This shift in redox potential may decrease
the redox buffering capacity of the ASL and therefore affect
the oxidation state of membrane proteins that could induce
downstream proinflammatory signaling [281, 282]. However,
it is not well understood how differences in extracellular
GSH could result in aberrant gene expression. Increased
or insufficiently buffered hydrogen peroxide production at
the apical membrane of CF epithelia by NADPH oxidases,
especially by the dual oxidase 1 (DUOX1) [283, 284], may
increase metalloproteinase-mediated release of ligands that
activate the ErbB1 signaling pathway resulting in augmented
CXCL8 production [273, 285] (Figure 2(c)).This is consistent
with the protective role of extracellularGSH supplementation
upon infection with Pseudomonas aeruginosa in CF cells that
reduced the release of CXCL8 and IL-6 [97, 286].
Direct GSH supplementation was explored as a thera-
peutic approach for CF as early as 1985. In this study the
authors demonstrated that aerosol administered GSH led to
an increase in BAL GSH and GSSG levels and decrease in
reactive oxygen species [287]. While this and other initial
studies were promising, showing an increase in BAL GSH
level and improved lung function [288], the improvement
could not be confirmed in a recent phase 2b trial [289].
Antioxidant treatment with N-acetylcysteine (NAC) that
has a weak antioxidant character but predominantly acts
through the replenishment of GSH in deficient cells [290] was
explored as alternative to GSH. Initial short-term studies (≤3
month) did not report a significant improvement in CF lung
function [291, 292]. Interestingly, administering high doses
of NAC three times daily reduced NE, neutrophil counts,
and CXCL8 in the sputum of CF patients [293]. A recent
phase 2 trial reports a significant relative increase in FEV
1
by
4.4% after 24-week treatment, which is predominantly due to
stabilization of the lung function in the treatment groupwhile
it declined in the control group [294] (Table 2).
Thiocyanate acts both as an antioxidant [295] and precur-
sor for the bactericidal hypothiocyanite [296]. Reduced level
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NeutrophilNeutrophil
Wild-type CF
[CXCL] ↑
(a)
SPLUNC1
GPCR
G
ErbB1 or -2 ENaC
H+
H+
H+
H+
H+
H+
CXCL8
pH ↓
(b)
Pro-ErbB1
ligand 
DUOX
MMP ErbB1
CXCL8
H2O2
[GSH] ↓
(c)
Figure 2: Putative mechanisms linking impaired anion transport to augmented epithelial chemokine signaling in secretory epithelia. (a)
Low ASL in CF results in elevated concentrations of CXCL chemokines due to the reduced liquid volume in the luminal compartment. The
increased concentration gradient enhances the neutrophil chemotaxis [250]. (b) Low ASL pH may directly activate chemokine expression
by activating acid-sensing signaling pathways via proton-sensing GPCRs, ErbB1, and ErbB2 or the soluble protein SPLUNC1. (c) The
decreased ROS buffering capacity of the ASL due to the reduced GSH concentration may promote hydrogen peroxide (H
2
O
2
) mediated
metalloproteinase (MMP) activation. These in turn cleave pro-erbB1 ligands resulting in erbB1 activation, thus initiating signaling pathways
that lead to the upregulation of chemokine expression [285].
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of thiocyanate in the epithelial lining fluid has been observed
in CF cells, CF mice [297], and CF patients [298]. Restoring
the thiocyanate levels in 𝛽-ENaC overexpressing mice, a
model for CF [70], using nebulized thiocyanate decreased the
bacterial burden after Pseudomonas aeruginosa infection and
attenuated neutrophil infiltration and reduced the levels of
the chemokine CXCL1 and cytokines IL-6 and TNF-𝛼 in the
BAL [299].
4. Conclusion
The discussed mechanisms, linking attenuated anion trans-
port to the inflammatory state in CF and other diseases, are
not mutually exclusive.Therefore it is likely that symptomatic
correction of any single one of these transport defects will
result in only minor benefit. This is evident by the results of
the clinical trials usingHTS to rehydrate themucus inCF that
resulted in only a modest improvement in lung function [241,
242] and using inhaled GSH to increase the ASL antioxidant
level that was not beneficial [289] (Table 2). Recent advances
to correct the underlying defect in CF by folding correctors
and gating potentiators of CFTR are promising, and drugs
targeting a subset of CF-causing mutations are approved [25,
28]. These compounds might be beneficial for other diseases
with an acquired loss of CFTR function phenotype like,
for example, COPD. Treatment with the gating potentiator
ivacaftor increased the WT-CFTR activity in cigarette smoke
exposed primary human bronchial epithelia and partially
reverted the smoke-induced mucociliary clearance defect
[300]. The University of Alabama recently announced a
phase I clinical trial with ivacaftor in COPD patients [301].
Considering the limited efficacy of this potentiator to increase
the open probability ofWT-CFTR [302] and the documented
downregulation of CFTR expression in COPD [117, 122],
stabilizing the proteinwith a corrector drugwould be another
promising strategy.
Alternative ion channels like TMEM16A or SLC26A9
may compensate for CFTRdysfunction [303]. For TMEM16A
this was attempted using the stable UTP analog denufosol
that stimulates P2Y-receptor-induced cytoplasmic calcium
signaling and thus channel activity [304] (Table 2). This
approach was unsuccessful [305], likely due to the rapid
desensitization and internalization of the P2Y-receptor [67,
306–308]. These limitations could be overcome by the
activator F that probably activates TMEM16A allosterically
without triggering cytosolic calcium signaling [309] and
that was shown to reduce CXCL8 secretion in a CF cell
model [67]. TMEM16A is widely expressed [132], including
in the airway smooth muscle where it is implicated in the
hyperresponsiveness in asthma [133, 310]. To target this
channel for therapy therefore requires the identification and
exploitation of an epithelial cell specific splice isoform [311]
or regulatory mechanism.
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